Drug Overview: Masitinib

  • ID: 4462133
  • Drug Pipelines
  • 45 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor receptor 3, platelet-derived growth factor receptor alpha/beta, lymphocyte-specific protein tyrosine kinase (Lck), Lck/Yes-related novel protein tyrosine kinase, and focal adhesion kinase. This makes the drug effective at controlling the survival, differentiation, and degranulation of mast cells, which are involved in oncogenic processes such as angiogenesis, tissue remodeling, and immunomodulation.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
masitinib: Prostate cancer
masitinib: Colorectal cancer (CRC)
masitinib: Asthma
masitinib: Pancreatic cancer

List of Figures
Figure 1: Masitinib for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of masitinib for prostate cancer
Figure 3: Drug assessment summary of masitinib for prostate cancer
Figure 4: Masitinib sales for prostate cancer across the five major EU markets, by country, 2017-26
Figure 5: Masitinib for colorectal cancer - SWOT analysis
Figure 6: Drug assessment summary for masitinib in colorectal cancer
Figure 7: Drug assessment summary for masitinib in colorectal cancer
Figure 8: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
Figure 9: Masitinib for asthma - SWOT analysis
Figure 10: Drug assessment summary of masitinib in asthma
Figure 11: Drug assessment summary of masitinib in asthma
Figure 12: Masitinib for pancreatic cancer - SWOT analysis
Figure 13: Drug assessment summary of masitinib in pancreatic cancer
Figure 14: Drug assessment summary of masitinib in pancreatic cancer

List of Tables
Table 1: Masitinib drug profile
Table 2: Masitinib Phase III trial in prostate cancer
Table 3: Masitinib Phase II data in prostate cancer
Table 4: Masitinib sales for prostate cancer across the five major EU markets, by country ($m), 2017-26
Table 5: Masitinib drug profile
Table 6: Masitinib Phase III trial in colorectal cancer
Table 7: Masitinib early-phase data in colorectal cancer
Table 8: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
Table 9: Patients treated with masitinib across the US and five major EU markets, by country, 2016-25
Table 10: Masitinib drug profile
Table 11: Masitinib Phase III trials in asthma
Table 12: Masitinib drug profile
Table 13: Masitinib Phase III data in pancreatic cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll